|Bid||228.00 x 100|
|Ask||260.00 x 400|
|Day's Range||243.45 - 247.22|
|52 Week Range||167.98 - 256.64|
|PE Ratio (TTM)||49.72|
|Earnings Date||Apr 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||259.31|
During the first two quarters of 2016, the Company, which provides genetic sequencing products to customers in the medical, academic, and pharmaceutical industries, repeatedly forecasted to investors an increase in sales of its HiSeq product system for the second half of 2016. On October 10, 2016, the Company disclosed that it had missed its earnings forecast for 2016Q3 by $18 million, driven by lower than expected sales of the HiSeq system. Then, on a November 1, 2016 investor conference call, the Company revealed that an increasing trend of customers preferring its other products over the HiSeq did not immediately show up in 2016Q3 but had been building over time, despite its prior forecasts of increased sales of the product.
Illumina Inc. shares rose in the extended session Friday after the DNA sequencing company and Bristol-Myers Squibb Co. announced they'll use Illumina's next-generation sequencing technology to develop ...
Drug giant Bristol-Myers Squibb is partnering with Illumina, the leading maker of DNA sequencing gear, to develop diagnostic tests that will pair with Bristol's cancer drugs.
Bristol-Myers Squibb Company and Illumina, Inc. today announced a collaboration that will utilize Illumina’s next-generation sequencing technology to develop and globally commercialize in-vitro diagnostic assays in support of Bristol-Myers Squibb’s oncology portfolio.
Illumina's new Lincoln Centre R&D campus in Foster City, developed by BioMed Realty, initially will consolidate 400 employees from four Bay Area locations. Included in the ranks is the company's new CEO.
Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types. The companies said the partnership will seek approval for a version of Illumina's test, TruSight Tumor 170, which will allow local laboratories to provide referring physicians with comprehensive genomic information, so that patients can be matched to the most appropriate therapeutic options. Larotrectinib directly targets an acquired rather than inherited genetic defect called TRK fusions.
Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday. The partnership will seek approval for a version of the Illumina's test, TruSight Tumor 170, as a companion diagnostic for Loxo's larotrectinib and another one of Loxo's experimental cancer drugs, across tumor types.
-Expands Illumina’ s Oncology Offerings for NextSeq™ 550 Dx with a Companion Diagnostic Version of TruSight™ Tumor 170 for Solid Tumors-. -Loxo Oncology to Utilize a Companion Diagnostic Version of TruSight ...
Illumina, Inc. and Loxo Oncology today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing based companion diagnostic with a pan-cancer indication.
Illumina, Inc. today announced that it will issue results for first quarter 2018 following the close of market on Tuesday, April 24, 2018.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Illumina, Inc.
With an ROE of 22.84%, Illumina Inc (NASDAQ:ILMN) outpaced its own industry which delivered a less exciting 10.71% over the past year. On the surface, this looks fantastic since weRead More...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ILMN. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $279 million.
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Illumina, Inc. . Illumina is a San Diego, CA-based company that provides sequencing and array-based solutions for genetic analysis.
Amedisys (AMED) is a healthcare services company with a focus on providing home care through three segments: home health, hospice, and personal care. Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating. Two analysts have given the stock a “buy” rating, while six analysts have given it a “hold” rating.
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory. The software has the ability to support data integrity, process adherence, and regulatory compliance. The system provides enhanced data software capabilities like sample management and data archiving as compared to the traditional CDS (chromatography data systems).
Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.
Illumina, Inc. announced today the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer , starting March 26, 2018. In his new role, Dr.